SEC Form 4 · accession 0001127602-16-037469
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Jan 19, 2016
Accepted (ET)
Jan 21, 2016 · 11:04 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 19, 2016 | M | 2,500 | $3.78 | A | 137,416 | D | |
| Common Stock | Jan 19, 2016 | M | 12,500 | $1.42 | A | 149,916 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $3.78 | Jan 19, 2016 | M | 2,500 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 2,500 | 99,260 | D |
| Emp. Stock Option (Right to Buy) | $1.42 | Jan 19, 2016 | M | 12,500 | D | Jan 1, 2014 | Jan 1, 2023 | Common Stock | 12,500 | 87,500 | D |